On October 8, 2026 Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company, reported that the United States Patent and Trademark Office ("USPTO") has granted a new Method of Use patent for certepetide [U.S. Patent No. 12,751,991] for the treatment of pancreatic cancer and other solid tumors, expiring May 2041.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The newly issued patent, titled "Methods for Treating Pancreatic Cancer and Other Solid Tumors," expands Lisata’s intellectual property protection for certepetide. The patent covers administering the Company’s proprietary cyclic peptide in combination with at least one anti-cancer agent or therapy to treat pancreatic cancer and other solid tumors, including metastatic, refractory, and drug-resistant cancers, by treating, inhibiting, and/or reducing tumor volume.
"This patent granted by USPTO secures important protection for the broad use of certepetide and provides added market exclusivity into November 2043, which is essential to support its continued development," stated David J. Mazzo, Ph.D., Chief Executive Officer of Lisata.
About Certepetide
Certepetide (formerly LSTA1), an internalizing RGD (arginyl-glycyl-aspartic acid or iRGD), cyclic peptide product candidate, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor. Certepetide also has been shown to modify the tumor microenvironment resulting in tumors which are more susceptible to immunotherapies. We and our collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability, and clinical activity in completed and ongoing clinical trials designed to test its ability to enhance the effectiveness of standard-of-care chemotherapy for pancreatic cancer.
(Press release, Lisata Therapeutics, OCT 8, 2026, View Source [SID1234673299])